Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

A few months back we discussed that the stock price of Biogen can see a rebound after falling 10% in a week, based on its historical performance. However, BIIB stock has seen a decline of over 12% since then, and it is down 7% in the last five trading days.

Will Biogen Stock Come Back Amid Pessimism Surrounding Aduhelm Rollout?

CAMBRIDGE, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), issued a positive opinion and has recommended granting marketing authorization for VUMERITY® (diroximel fumarate) in the European Union (EU). VUMERITY is a next-generation oral fumarate for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS). An estimated 2.8 million people live with MS across the globe, with some European countries demonstrating the highest prevalence of MS in the world.1

CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis

Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy

Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy

Biogen Inc's (NASDAQ: BIIB) Spinraza (nusinersen), spinal muscular atrophy (SMA) drug launched in early 2017, faces new competition from Roche Holdings AG's (OTC: RHHBY) oral entrant Evrysdi (risdiplam).  Biogen has unveiled plans to test Spinraza in patients who've already been treated with Evrysdi.

Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know

CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to initiate a global Phase 3b clinical study, ASCEND. The ASCEND study is designed to evaluate the clinical outcomes and assess the safety of a higher dose of nusinersen* in children, teens and adults with later-onset spinal muscular atrophy (SMA) following treatment with Evrysdi® (risdiplam).

Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)

DocuSign

Marathon Digital Holdings

Markets are coming out of a slightly red week. Sentiment has soured, so that leaves the door open to find good stocks to buy cheaply.

3 Quality Stocks to Buy From the Bargain Bin

Biogen's (BIIB) new Alzheimer's drug, Aduhelm, can bring in huge revenues, if successfully commercialized.

Biogen (BIIB) Alzheimer's Drug Aduhelm Sees Slow Launch, Stock Down

The U.S. launch of Alzheimer's disease drug Aduhelm is off to a sluggish start.

Why Biogen Stock Is Sinking This Week

Biogen Inc (NASDAQ: BIIB) shares are trading lower by 7% at $298.83 following reports the company's CEO highlighted a slower-than-anticipated launch of Aduhelm. Biogen announced on June 7 that the U.S. Food and Drug Administration granted accelerated approval for Aduhelm as the first and only Alzheimer's disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain.

Why Biogen Shares Are Falling

Morgan Stanley

Biogen Inc. (BIIB) CEO Michel Vounatsos Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)

Aduhelm's commercial launch isn't off to a strong start.

Why Biogen Stock Is Slipping Today

The biotech giant said that the launch of controversial Alzheimer's disease drug, Aduhelm, faced some "near-term challenges,"

Biogen Stock Is Tumbling Because Its Alzheimer's Drug Rollout Isn't Going So Well

Cassava Sciences Inc

These two biotechs are going after a significant market: Alzheimer's.

Better Buy: Biogen vs. Cassava Sciences

It may be much ado about nothing, but Biogen Inc. ( BIIB , Financial) investors can't help but be a bit nervous that the U.S. Congress has asked for information from the Food and Drug Administration concerning the agency's accelerated approval of the Cambridge, Massachusetts-based biotech's new Alzheimer's drug, Aduhelm. Following approval, the FDA came under scathing criticism from some scientists and staff, who questioned the treatment's effectiveness, mounting further pressure on the agency that has come under fire for clearing the drug.

Could Biogen's Alzheimer's Drug Be in Trouble?

Biogen scooped an FDA approval for its ADUHELM therapy for Alzheimer's.

Biogen: Zero Dollar Hardball

Biogen's (BIIB) new Alzheimer's drug, Aduhelm should bring in huge revenues, if successfully commercialized.

Biogen (BIIB) Stock Up This Year So Far on Aduhelm Approval

AstraZeneca

Clovis Oncology

Denali Therapeutics

Eli Lilly

Morphosys AG - ADR

Pfizer

Clovis Oncology Inc. ( CLVS , Financial) and Denali Therapeutics Inc. ( DNLI , Financial) are among the most likely biotechs to be acquired, according to industry publications. Denali, by far, would be the most expensive of the pair with a market cap of $6.4 billion, while Clovis is far more digestible with a market value of only $567 million.

Biotech Takeovers Moved at Snail's Pace in 2nd Quarter

Biogen Inc (NASDAQ: BIIB) is providing its controversial and expensive new Alzheimer's drug, free of charge for some patients amid slow claim reviews by Medicare, reports Reuters, citing sources familiar with the situation. 'Aduhelm' given as a monthly infusion was approved by the FDA in June even though one of Biogen's two large trials failed to show a benefit for patients diagnosed with the incurable mind-wasting disease.

Amid Medicare Uncertainty, Biogen Offers Its Alzheimer's Drug For Free

Aduhelm costs $56,000 a year and some insurers have been slow to make reimbursements, Reuters reported. Doctors also are questioning the drug's effectiveness.

Biogen Is Giving Away Its Controversial Alzheimer's Drug: Report

It's bound to happen eventually, so it's best to have a contingency plan.

Biogen: What to Do When Your Investment Thesis Is Disproven

A recent regulatory approval could make this company worth serious consideration.

Warren Buffett Sold Off This Biotech Stock. Should You?

Axsome Therapeutics

Here are three reasons why a buyout just might happen.

Could Biogen Acquire Axsome Therapeutics?

AbbVie

Bristol-Myers

General Motors

Kroger

Merck

Buffett stocks are a hot topic among investors as they look to go long on some fresh plays. Kroger and Aon are among Berkshire's favorites.

7 Buffett Stocks to Buy (and Sell) if You Want to Be Like Berkshire

Yesterday, Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial)( BRK.B , Financial) published its 13F report for the period ending June 30.

Warren Buffett Sells Biotech Holdings After a Year

Buffett's company established stakes in Merck, AbbVie, and Bristol Myers Squibb in the second half of last year, yet it slashed all three positions.

News for Biogen Stock (BIIB)